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Abstract
Background: A major player in the process of metastasis is the actin cytoskeleton as it forms key structures in both invasion
mechanisms, mesenchymal and amoeboid migration. We tested the actin binding compound Chondramide as potential
anti-metastatic agent.
Methods: In vivo, the effect of Chondramide on metastasis was tested employing a 4T1-Luc BALB/c mouse model. In vitro,
Chondramide was tested using the highly invasive cancer cell line MDA-MB-231 in Boyden-chamber assays, fluorescent
stainings, Western blot and Pull down assays. Finally, the contractility of MDA-MB-231 cells was monitored in 3D
environment and analyzed via PIV analysis.
Results: In vivo, Chondramide treatment inhibits metastasis to the lung and the migration and invasion of MDA-MB-231
cells is reduced by Chondramide in vitro. On the signaling level, RhoA activity is decreased by Chondramide accompanied
by reduced MLC-2 and the stretch induced guanine nucleotide exchange factor Vav2 activation. At same conditions, EGF-
receptor autophosphorylation, Akt and Erk as well as Rac1 are not affected. Finally, Chondramide treatment disrupted the
actin cytoskeleton and decreased the ability of cells for contraction.
Conclusions: Chondramide inhibits cellular contractility and thus represents a potential inhibitor of tumor cell invasion.
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Introduction
Metastasis is the primary cause of death in cancer [1]. One
reason for this is a lack of efficient therapies against metastasis.
Currently, metastatic tumors can only be treated once they have
established. Therapies targeting the initial steps of metastasis (local
invasion, intravasation, arrest and extravasation) are still lacking,
but might be a clinically attractive option, e.g. in cases where
tumor resection might cause spreading of malignant cells. The
formation of cancer colonies at sites distant from the primary
tumor requires cellular properties distinct from those within the
primary tumor. Thus, established therapies against primary
tumors like doxorubicin or cisplatin are less effective against
invasive cells. The resistance of invasive cells arises from the
upregulation of anti-apoptotic genes and the downregulation of
pro-apoptotic genes compared to primary tumor cells [2]. In
addition to this anti-apoptotic phenotype, invasive cells show a far
more plastic and migratory phenotype. This phenotype is
characterized by cellular deformation involving the formation of
protrusions and new adhesions to surfaces as well as cellular
contractility, which is required for rear retraction and cellular
transmigration [3]. In all these processes, the actin cytoskeleton
plays a pivotal role and underlies a constant re- and disassembly to
form protrusions and stress fibers [4,5]. The importance of the
actin cytoskeleton during metastasis is reflected at the level of actin
regulating proteins as many of those are deregulated in metastatic
cells [6,7].
Invasive cells show two modes of migration: first, the
mesenchymal type and, second, the amoeboid type of migration
[8–10], which both depend on contractility. In the mesenchymal
migration, cells show an elongated morphology with lamellipodial
protrusions and high proteolytic activity, which is required in
addition to contractility. Contrarily, the amoeboid migration
mode is totally independent of proteolysis and can be induced as
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an escape mode when proteolysis is inhibited. In this migration
type, cells show rounded shape and invasion through the matrix is
primarily mediated via cellular contractility. The underlying
signaling pathway involves Rho/ROCK and myosin to induce
the actin dependent contractile force. In both processes, the actin
cytoskeleton plays a central role either for the formation of
protrusions or the contraction of the cell. Therefore, the actin
machinery represents an attractive target to address metastatic
cells.
Interestingly, a large number of natural compounds bind the
actin cytoskeleton and interfere with actin dynamics [11]. Since
actin is of central importance for most organisms, including
parasites and fungi, nature most likely has favored the evolution of
secondary metabolites which target actin one way or the other.
Nevertheless, the use of these natural compounds has been
neglected due to the ubiquitous occurrence of actin and possible
severe side effects. However, the successful clinical use of
microtubule binding agents as anti-cancer drugs mitigates this
argument [12]. An actin binding compound evolved from natural
selection is Chondramide. Chondramide is a cyclodepsipeptide
isolated from the myxobacterium Chondromyces crocatus [13]. It
induces actin polymerization in vitro and has only been shown to
be cytotoxic but its detailed mode of action on cancer cells has not
been elucidated so far [14].
We hypothesize that metastasis can be inhibited using the actin
polymerizing compound Chondramide and elucidate its potency
in vitro and in vivo. Here, we can show that Chondramide inhibits
cancer cell migration and invasion in vitro involving signaling
pathways, which influence cellular contractility. Further, we




Chondramide was isolated as previously described [15] and
dissolved and stored in DMSO. For experiments, Chondramide
(Ch) was dissolved in growth medium containing DMSO at a
maximum of 0.1% (v/v).
Cell culture
All cell lines were cultured under constant humidity at 37uC and
with 5% CO2 in an incubator (Heraeus, Hanau, Germany).
MDA-MB-231 cells were purchased from Cell Line Services
(Eppelheim, Germany) and cultivated in dulbecco’s modified
eagle’s medium (DMEM, PAN Biotech, Aidenbach, Germany)
supplemented with 10% FCS. 4T1-Luc cells were purchased from
Caliper Life Sciences (Alameda, CA, USA).
Figure 1. Chondramide diminishes metastasis in vivo. 16105 4T1-Luc cells were injected intravenously into pretreated (0.5 mg/kg ChB) and
untreated BALB/cByJRj mice. (A) 8 days after cell inoculation mice were sacrificed, lungs were harvested and used for recording bioluminescence
signals. Each lung was imaged from the dorsal and ventral side. Color bar scales were equalized. (B) Quantitative evaluation of metastasis to the
lungs. Region of interest were defined (ROI) and total luciferin signal in ROIs was calculated as photons/second/cm2 (total flux/area). Ten lungs per
group, *, p,0.05 (t-test, unpaired). (C) Mouse weight over treatment period. Weight of treated (ChB) and untreated (DMSO) mice from day of cell
inoculation (day 0) to euthanasia (day8) is shown for each group.
doi:10.1371/journal.pone.0112542.g001
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In vivo experiment
20 BALB/c mice were divided into two groups (treatment and
control) and inoculated via the tail vein with 16105 syngenic
mammary tumor cells stably transfected with the luciferase gene
(4T1-Luc cells). The treatment group was premedicated intrave-
nously with 0.5 mg/kg Ch in 5% DMSO/PBS 24 h and 4 h
before tumor cell injection. The control group was injected with
equal amounts of 5% DMSO/PBS. On day eight after tumor cell
inoculation, mice were anesthetized with 2% isoflurane in oxygen
and 6 mg Na-luciferin were injected intraperitoneally. Thereafter,
mice were sacrificed through cervical dislocation. Lungs were
harvested and imaged using the IVIS Lumina system with Living
Image software 3.2. Images were interpreted with equalized color
bar scales, measuring the photon emission of the mice. For
quantification of the lung signals, the images of the harvested lungs
were analyzed. Regions of Interest (ROIs) were defined and total
signals per ROI were calculated as photons/second/cm2 (total
flux/area). During the experiment, mice were weighed every
second till third day. All animal experiments were conducted
according to the guidelines of the German law for protection of
animal life and approved by the Government of Upper Bavaria
(Permit No. 559999.2-1-54-2532-107-13).
Migration and invasion assays
For Boyden chamber assays, 56104 MDA-MB-231 or 4T1-Luc
cells were seeded per well in a Boyden chamber with a pore size of
8 mM (Corning, New York, USA) without FCS. For negative
control, the lower compartment was filled with medium lacking
FCS, whereas for positive control and treated samples, the lower
compartment was filled with full medium containing 10% FCS.
After 16 h, cells were fixed and stained with crystal violet/
methanol. Cells on top of the filter were removed with a q-tip and
bottom sides were photographed using an Axiovert25 microscope
(Zeiss), 106 objective, and a Canon EOS 450C camera (Tokyo,
Japan). Images were analyzed using the ImageJ plugin cell
counter. The invasion assay was performed analog to Boyden
chamber assays except for filters being coated with 100 ml 10%
matrigel (Schubert&Weiss-OMNILAB, Munich, Germany) and
polymerized before seeding and an incubation time of 48 h.
Fluorescence imaging
MDA-MB-231 cells were seeded in an IBIDI-mSlide (IBIDI,
Martinsried, Germany) and cultivated overnight plus treatment
period. F-actin was stained with rhodamin-phalloidin (1:400, R
415, Molecular Pobes/Invitrogen) and nuclei with bisBenzimide
H33342 (Sigma-Aldrich, St. Louis, MO, USA). The following
antibodies were used: Integrin a5 (Millipore, Upstate), p(S19)-
MLC (Cell Signalling Technology, Danvers, MA, USA) and
Vinculin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Images were obtained with a Zeiss LSM 510 META (Zeiss,
Oberkochen, Germany) or Leica TCS SP8 SMD confocal
microscope (Leica, Mannheim, Germany).
Adhesion assay
Pretreated MDA-MB-231 cells were trypsinized, suspended in
DMSO or Ch containing medium and allowed to adhere on
fibronectin, collagen G or plastic for 1 h. Cells were fixed with 4%
para-formaldehyde and stained for F-actin. Images were taken on
a Zeiss LSM 510 META confocal microscope (106objective) and
counted for adhering cells.
Western blotting
Western blot analysis was performed as described previously
[16]. The following antibodies were used: GAPDH, MLC2, Vav2,
p(Y172)Vav2 (Santa Cruz Biotechnology), p(S473)Akt, Akt,
p(Y1068)EGF-R, EGF-R, p(T202,Y204)Erk, Erk, p(S19)MLC2
(Cell Signalling Technology), Rac (23A8, Merck Millipore,
Darmstadt, Germany), Rho (Thermo Scientific, Bonn, Germany).
Rho GTPase pull down experiments
Activation of Rac1 and Rho were induced by adding 100 ng/
ml EGF for 5 min to the medium followed by a pull down assay
according to manufacturer’s protocol (Thermo Scientific, Bonn,
Germany).
Contractility measurement
Yellow-green microbeads of 1 mm diameter, 2% solids (Life-
Technologies, Carlsbad, CA, USA) were mixed with matrigel in a
ratio of 1:4 (v/v) on ice. The bead/matrigel mixture was mixed
with pretreated MDA-MB-231 cells, 56106 cells/ml, in a ratio of
2:1 (v/v) and pipetted into an angiogenesis slide (ibidi, Martins-
ried, Germany). Matrigel was allowed to polymerize for 1 h at
37uC, 5% CO2 in humidified atmosphere, before samples were
covered with culture medium. Images were taken using an open
U-iMIC fluorescent microscope (TILL Photonics GmbH, Gräfelf-
ing, Germany) with 206 objective. Stacks of 5 slices around the
cell equatorial plane with a 2 mm distance were taken over 4 h
with 15 min intervals. Three optical slices at the equatorial plane
were used for maximum intensity projection (imageJ) and images
were standardized to 3006300 px with one cell at the image
center. Movies of fluorescent beads were analyzed by particle
image velocimetry (PIV) analysis with a customized MatPIV
software package for Matlab. Interrogation windows were 32632
pixels, i.e. 21621 mm. A single iteration was performed with
62.5% overlap. The resulting velocity vectors were filtered with
the set of filters included in the standard MatPIV package to
smooth the vector fields. As the sample observation is restricted to
2D, z-components of the velocity are not seen and the PIV analysis
only gives velocities projected into the observation plane. The
obtained velocity field was averaged on each grid point over each
Figure 2. Chondramide leads to reduction of stress fibers and F-actin aggregation. MDA-MB-231 cells were treated with 200 nM ChA or
DMSO for indicated time periods, fixed and stained for F-actin and nuclei (n = 3). Bar represents 20 mm.
doi:10.1371/journal.pone.0112542.g002
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frame of the observation period to further remove fluctuations that
occur on short time scales. For quantitative comparison, the radial
velocity towards the cell center per data was calculated. Minimum
13 cells per condition out of three independent experiments were
recorded and analyzed.
Measurement of sub-diploid DNA content
To detect apoptotic cells, sub-diploid DNA content (i.e.
fragmented nuclei) was measured as described by Nicoletti et al.
[17]. Cells were permeabilized and stained with propidiumiodide
(50 mg/ml), followed by flow cytometry using a FACSCalibur
(Becton Dickinson, Heidelberg, Germany).
Figure 3. Treatment with Chondramide reduces breast cancer cell migration, invasion and adhesion. (A) Chondramide treated and
untreated MDA-MB-231 cells were allowed to migrate in a Boyden chamber for 16 h. (B) Chondramide inhibits invasion of MDA-MB-231 cells through
matrigel in Boyden chamber (48 h). A,B: For positive control (PC) lower compartment was filled with medium plus 10% FCS, for negative control (NC)
only medium without FCS was added. *, p,0.05 One-way ANOVA, Tukey post-test, n = 3. (C) Pretreated MDA-MB-231 cells were seeded freshly on
indicated surfaces and counted after fixation. *, p,0.05 One-way ANOVA, Tukey post-test, n = 3. (D) Cells from C were stained for F-actin, nuclei and
vinculin. Bar represents 50 mm.
doi:10.1371/journal.pone.0112542.g003
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Statistical analysis
The number of independently performed experiments and the
statistical tests used are stated in the respective figure legend.
Graph data represent means 6 SEM. Statistical analysis was
performed with the software GraphPad Prism Version 5.04
(GraphPad Software, Inc., La Jolla, CA, USA). Statistical
significance is assumed if p#0.05. For the in vivo metastasis assay
the statistical power was calculated to be 0.85 using G*power
software.
Results
Chondramide diminishes metastasis in vivo
First, we evaluated the pharmacological, anti-metastatic poten-
tial of Chondramide (Ch) in vivo. To this end, we employed a
4T1-Luc metastatic mouse breast cancer model [18–20]. Hereby,
a murine 4T1-Luc mammary cancer cell line expressing recom-
binant luciferase is injected intravenously in BALB/cByJRj mice.
These luciferase expressing cancer cells metastasize to the lung and
can be detected via bioluminescent measurement. The evaluation
of the bioluminescent signal in the lungs of untreated and Ch
treated mice revealed a significant reduction of metastasis for Ch
treated mice compared to control mice (Fig. 1a,b). Over the
treatment period, the weight of Ch treated mice stayed constant
indicating a good tolerance of 0.5 mg/kg Ch during application
(Fig. 1c).
Chondramide affects stress fibers of highly invasive
cancer cells
As a model for highly invasive cancer cells the cell line MDA-
MB-231 was used for in vitro experiments. In actin stainings of
MDA-MB-231 cells, stress fibers seemed altered as compared to
control cells. Since in parallel actin aggregates close to the nucleus
after 4 and 8 h were observed (Fig. 2), this might be due to
depletion of available actin. Alternatively, binding of the F-actin
probe phalloidin might have been competitively inhibited by
Chondramide. After 24 h the cells were completely condensed
while no induction of apoptosis was observed (Fig. S1). These
condensed cells recovered to the original cell size when Ch was
removed (Fig. S2).
Figure 4. Chondramide affects activation of the RhoGTPase Rho. (A) A Rac1 pull down was performed for untreated and Chondramide
treated cells (24 h) upon EGF-stimulation (5 min). (B) After same treatment a Rho pull down was conducted. (C) Myosin light chain 2 (MLC2) was
analyzed on its activation state via Western blot analysis upon EGF stimulation (5 min). A,B,C: Left panel: one representative Western blot is shown.
Right panel: Densitometric analysis of Western blots. *, p,0.05 One-way ANOVA, Tukey post-test, n = 3.
doi:10.1371/journal.pone.0112542.g004
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Chondramide abrogates EGF induced migration, invasion
and adhesion in vitro
Next, the effect of Ch on the transmigration of MDA-MB-231
was tested in a Boyden chamber assay. The migration was
inhibited significantly by Ch at 30 nM or 100 nM down to 70% or
60%, respectively (Fig. 3a). Similar effects (62% and 54%,
respectively) were observed with the 4T1-Luc cells, which were
also used for the in vivo assay (Figure S3). To study the effect of Ch
on invasiveness, matrigel filled Boyden chambers were used. Here,
Ch decreased cell invasion at 30 nM and 100 nM to less than 50%
(Fig. 3b).
To further elucidate the effect of Ch on cell migration, a central
step, cell adhesion, was tested. Here, Ch reduced the attachment of
cells to plastic, fibronectin and collagen G at 100 nM, however, not
at 30 nM (Fig. 3c). This indicates, that anti-adhesive properties of
Ch could contribute to an anti-migratory effect, yet, this seems not
to be the only factor diminishing cancer cell migration, at least at
30 nM concentration of the compound. Fluorescent stainings of the
adhering cells revealed that cells treated with 30 nM Ch showed
normal cell morphology whereas the few adhering cells at 100 nM
Ch were not able to spread (Fig. 3d), which also indicated additional
mechanisms at 30 nM Ch.
Chondramide lowers the activity of the RhoGTPase Rho
but not Rac1
To investigate whether stress fiber reduction seen in Fig. 2b is a
direct effect of Ch or induced due to alterations in signaling, the
upstream effectors of the actin-cytoskeleton were tested for their
activity. Therefore, the RhoGTPases Rac1 and Rho were
analyzed using pull-down assay. We could see no alterations in
the amount of GTP-bound Rac1 (Fig. 4a). However, following
EGF stimulation, the level of GTP-bound Rho was clearly reduced
at 30 nM Ch (Fig. 4b). The diminished activity of Rho could be
confirmed further downstream as the regulatory myosin light
chain 2 (MLC2) was less phosphorylated at Ser19 after treatment
with Ch (Fig. 4c).
Chondramide has no effect on the activation of the
EGF-receptor and downstream signaling
Next, the underlying mechanism of reduced Rho activity by Ch
was evaluated. As the Rho GTPases were activated through
extracellular EGF stimulation in our experiments, we examined
the EGF-receptor (EGFR) on its ability for autophosphorylation.
The autophosphorylation at Y1068 of the EGFR was not affected
by Ch treatment (Fig. 5). Neither 30 or 100 nM Ch nor a very
short or longer time point showed any changes in the phosphor-
ylation state. Concomitant with that, the phosphorylation status of
the downstream effectors to EGFR, Akt and Erk, at S473 or
T202Y204, respectively, showed no effect of Ch treatment
compared to positive control (Fig. 5). This data indicates normal
activation of these pathways under Ch treatment.
Chondramide diminishes cellular contractility and the
Rho activating GEF Vav2
The activation of the RhoGTPase Rho can also be mediated via
intra- or extracellular forces. Thus, we tested the ability of MDA-
Figure 5. Chondramide does not influence EGF-R signalling. MDA-MB-231 cells were treated with Chondramide (1 or 24 h), stimulated with
EGF (5 min) and analyzed via Western blot analysis on EGFR, Akt and Erk. Left panel: one representative Western blot is shown. Right: Densitometric
analysis of Western blots. *, p,0.05 One-way ANOVA, Tukey post-test, n = 3.
doi:10.1371/journal.pone.0112542.g005
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MB-231 cells to exert contractile force. Cellular force on
surrounding matrix can be visualized as exerted forces result in
matrix deformation which can be imaged by embedded fluores-
cent beads [21,22]. To this end, cells were seeded in matrigel
containing fluorescent beads and images were taken over 4 h.
Control cells revealed a clear contractile force on the surrounding
matrix as seen by bead movement towards the cell (Fig. 6a, and
movies S1 and S2). The bead movement was reduced at 30 nM
and even more at 100 nM Ch (Fig. 6b), thus, indicating a
reduction of intracellular originating force in cells treated with Ch.
Intra- and extracellular force lead to the activation of guanine
nucleotide exchange factors (GEFs), e.g. Vav2, which activates
RhoA. The activity dependent phosphorylation site Y172 of Vav2
was less phosphorylated under Ch treatment (Fig. 6c) indicating
reduced activation of the GEF Vav2 after Ch application.
Discussion
Cellular contractility is of utmost importance in cancer cell
invasion. Classic migration depends on contractility as the cell rear
has to be retracted after cell protrusion and formation of new
adhesions in the migration direction. Further, the amoeboid
migration of cancer cells is mostly driven by contractile force
depending on Rho/ROCK signaling but not proteolysis [9,10].
Figure 6. Chondramide diminishes contractility. (A) MDA-MB-231 cells were pretreated for 24 h as indicated, embedded in matrigel containing
fluorescent beads and pictures were taken over 4 h every 15 min. Cellular, contractile force on the surrounding matrix was visualized via bead
movement towards the cell and analyzed using PIV analysis. Upper panel: Representative images of cells (red) and fluorescent beads (green) t = 0.
Lower panel: PIV analysis of bead velocity in the 2D projection. Color codes show bead velocity indicating applied force. Direction of vectors indicates
averaged direction of bead movement. (B) For quantitative analysis the radial velocity (bead velocity towards the cell center) per data point was
calculated. Minimum 13 cells per condition were analyzed. *, p,0.05 One-way ANOVA, Tukey post-test. (C) Phosphorylation of the Rho-GEF Vav2 was
tested via Western blot analysis upon EGF stimulation (n = 3); * p,0.05 vs. control, One-way ANOVA, Tukey post-test.
doi:10.1371/journal.pone.0112542.g006
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According to literature, the highly invasive cell line MDA-MB-231
follows the scheme of an amoeboid migration through matrigel,
requiring a contractile uropod dependent on RhoA and MLC-2
activity [22]. During this process, cells exert contractile force to the
surrounding matrix. Accordingly, we observed a matrix deforma-
tion by migrating MDA-MB cells, as shown by fluorescent bead
movement. This bead displacement was reduced after Chondra-
mide treatment indicating reduced contractile force of the cell due
to treatment. The observation that migration, invasion and
contractility are inhibited at the same concentration of Chon-
dramide suggests that the reduction of contractility is the
underlying cause for these functional defects.
The signaling cascade leading to contractility, via Rho/ROCK
and myosin, is known to enhance invasion when upregulated
[23,24]. Chondramide treatment diminishes the activity of Rho
and MLC2. Other factors like Rac1 or EGFR and its downstream
factors, Akt and Erk, were not affected at same conditions. Thus,
Chondramide primarily inhibits the pro-contractile signaling
cascade.
Interestingly, a connection between contractile force and RhoA
activation is reported not only from Rho being required for
contractility but also the other way around that contractile force
induces RhoA activation [25]. In this context, Vav2 has been
shown to be induced by applied forces in the form of stretching in
mesangial cells [26] and Vav2 is known to be necessary for a full
activation of RhoA in MDA-MB-231 cells [27]. These observa-
tions are in line with our findings revealing that Vav2 and RhoA
are less active in Chondramide treated cells. According to our in
vitro data, adhesion is not yet affected at 30 nM Chondramide,
while transmigration and Rho activity and phorphorylation of
MLC2 are. We suggest that Chondramide may reduce contrac-
tility via reduced intra-cellular force diminishing Rho activation.
The approach to target the actin cytoskeleton has been thought
to be too toxic for clinical application [28]. However, the feasibility
to target actin is shown here in an in vivo mouse model of tumor
metastasis. Herein, treatment with Chondramide diminishes the
metastasis of mammary cancer cells to the lung significantly. As
migration is reduced at lower concentrations and shorter time
points than nuclear fragmentation occurs, we propose that the
inhibitory effect on metastasis is not due to an apoptotic effect but
the abrogation of migration and invasion. The dose of 0.5 mg/kg
was well tolerated as the body weight of treated mice stayed
constant throughout the observation period. Although there is still
room for further development, e.g. specific targeting, we could
show a pharmacological effect for Chondramide on metastasis in
vivo without acute toxicity. In our in vivo treatment regime we
tried to keep close to a potential clinical setting, and, thus, chose
systemic administration of Chondramide. This, of course, means
that cells other than tumor cells (e.g. endothelial cells) might have
been affected by the compound, and that we cannot dissect, which
step of metastasis might have been primarily affected (adhesion,
extravasation, migration as such, trapping of tumor cells in the
pulmonary microcirculation). Due to the short presence of
compound (administration 24 h and 4 h before cell application
vs. detection of metastasis after 8 days), it is unlikely that later steps
of metastasis formation (survival, growth) might have been
influenced by Chondramide.
As therapies against cancer metastasis are still missing, more
efforts need to be made in research addressing metastatic cancer
cells. This work provides evidence that actin is a suitable target to
inhibit cancer cell migration, and gives first insights into
underlying mechanisms. Combining actin binding natural com-
pounds with specific targeting strategies could lead to a powerful
weapon to treat tumor metastasis.
Supporting Information
Figure S1 Reduction of migration is not due to cell
death. Nuclear fragmentation was measured in MDA-MB-231
cells after ChA treatment and PI staining. *, p,0.05 One-way
ANOVA, Tukey post-test, n = 3.
(TIF)
Figure S2 Aggregation of cells is reversible. MDA-MB-
231 cells were treated with DMSO, 200 nM ChA for 40 h or with
200 nM ChA for 24 h and then additional 16 h without ChA.
Cells were fixed and stained for F-actin and nuclei (n = 3). Scale
bar represents 50 mm.
(TIF)
Figure S3 Reduction of migration in 4T1-Luc cells.
Chondramide treated and untreated 4T1-Luc cells were allowed
to migrate in a Boyden chamber for 16 h. For positive control (PC)
lower compartment was filled with medium plus 10% FCS, for
negative control (NC) only medium without FCS was added. *, p,
0.05 One-way ANOVA, Tukey post-test, n = 3.
(TIF)
Movie S1 Chondramide diminishes contractility. MDA-
MB-231 cells were untreated (movie 1) or pretreated for 24 h with
100 nM chondramide, embedded in matrigel containing fluores-
cent beads and pictures were taken over 4 h every 15 min. Red:
labeled cell, green: fluorescent beads. Bead movement toward the
cell (contractility) is much lower in the treated sample. For
quantitative evaluation see Figure 6.
(AVI)
Movie S2 Chondramide diminishes contractility. MDA-
MB-231 cells were untreated (movie 1) or pretreated for 24 h with
100 nM chondramide, embedded in matrigel containing fluores-
cent beads and pictures were taken over 4 h every 15 min. Red:
labeled cell, green: fluorescent beads. Bead movement toward the
cell (contractility) is much lower in the treated sample. For
quantitative evaluation see Figure 6.
(AVI)
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